By blocking the tyrosine kinase domain of HER2, lapatinib elicits the accumulation of HER2 on the cell membrane [52] in the BC cell lines BT474 and SKBr3, increasing trastuzumab-dependent cytotoxicity in combination with trastuzumab [53] (Figure 1). This evidence concerns the gene ERBB2 and breast cancer.